CA2400215A1 - Peptides de liaison hla et utilisations de ces derniers - Google Patents

Peptides de liaison hla et utilisations de ces derniers Download PDF

Info

Publication number
CA2400215A1
CA2400215A1 CA002400215A CA2400215A CA2400215A1 CA 2400215 A1 CA2400215 A1 CA 2400215A1 CA 002400215 A CA002400215 A CA 002400215A CA 2400215 A CA2400215 A CA 2400215A CA 2400215 A1 CA2400215 A1 CA 2400215A1
Authority
CA
Canada
Prior art keywords
peptides
peptide
cells
ctl
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002400215A
Other languages
English (en)
Inventor
Alessandro Sette
John Sidney
W. Martin Kast
Scott Southwood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epimmune Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2400215A1 publication Critical patent/CA2400215A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne les moyens et les procédés qui permettent de sélectionner des peptides immunogènes et des compositions de peptides immunogènes qui sont capables de lier spécifiquement des glycoprotéines codées par des allèles HLA et d'induire une activation des cellules T dans des cellules T restreintes par l'allèle. Ces peptides sont utiles pour solliciter une réponse immunitaire contre un antigène désiré.
CA002400215A 2000-02-23 2000-02-23 Peptides de liaison hla et utilisations de ces derniers Abandoned CA2400215A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2000/004655 WO2001062776A1 (fr) 2000-02-23 2000-02-23 Peptides de liaison hla et utilisations de ces derniers

Publications (1)

Publication Number Publication Date
CA2400215A1 true CA2400215A1 (fr) 2001-08-30

Family

ID=21741082

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002400215A Abandoned CA2400215A1 (fr) 2000-02-23 2000-02-23 Peptides de liaison hla et utilisations de ces derniers

Country Status (8)

Country Link
EP (1) EP1263775A4 (fr)
JP (1) JP2003524016A (fr)
CN (1) CN1452634A (fr)
AU (1) AU2000232427A1 (fr)
BR (1) BR0017136A (fr)
CA (1) CA2400215A1 (fr)
MX (1) MXPA02008219A (fr)
WO (1) WO2001062776A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2370413A1 (fr) * 1999-06-29 2001-01-04 Epimmune Inc. Peptides de liaison a hla et leurs utilisations
WO2001074845A2 (fr) * 2000-03-31 2001-10-11 Aventis Pasteur Limited Peptides immunogenes derives d'antigene d'enveloppe specifique de la prostate (psma) et leur utilisation
US20030113919A1 (en) * 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
US8202841B2 (en) 2004-06-17 2012-06-19 Mannkind Corporation SSX-2 peptide analogs
JP4475469B2 (ja) * 2005-01-25 2010-06-09 日本電気株式会社 Ｈｌａ結合性ペプチド、それをコードするｄｎａ断片および組み換えベクター
AU2006259307B2 (en) 2005-06-17 2012-12-20 Mannkind Corporation Epitope analogues
ES2413079T3 (es) * 2005-06-17 2013-07-15 Mannkind Corporation Métodos y composiciones para desencadenar respuestas inmunitarias multivalentes contra epítopos dominantes y subdominantes expresados en células cancerosas y estroma tumoral
CN1948333B (zh) * 2005-10-14 2010-12-08 中国人民解放军第二军医大学 一种新的hPEBP4蛋白来源的HLA-A2限制性表位多肽及其应用
US7632814B2 (en) * 2006-09-07 2009-12-15 University Of South Florida HYD1 peptides as anti-cancer agents
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
EP2391635B1 (fr) 2009-01-28 2017-04-26 Epimmune Inc. Polypeptides de liaison de pan-dr et leurs utilisations
WO2011115688A2 (fr) 2010-03-19 2011-09-22 H. Lee Moffitt Cancer Center & Research Institute Inhibiteurs des interactions de l'intégrine pour traiter le cancer
WO2012033142A1 (fr) * 2010-09-08 2012-03-15 学校法人 埼玉医科大学 Vaccin liposomal contre le virus de l'hépatite c
WO2015048477A1 (fr) 2013-09-27 2015-04-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Conjugués de peptide cyclique et procédés d'utilisation
CN110049774A (zh) 2016-10-07 2019-07-23 恩特罗姆公司 肿瘤相关抗原表位的小型生物群序列变体
CN117801069A (zh) 2016-10-07 2024-04-02 恩特罗姆公司 用于癌症疗法的免疫原性化合物
CN117801066A (zh) 2016-10-07 2024-04-02 恩特罗姆公司 用于癌症疗法的免疫原性化合物
JP7197481B2 (ja) 2016-11-30 2022-12-27 アドバクシス， インコーポレイテッド 反復性がん突然変異を標的とする免疫原性組成物およびその使用の方法
EP3707152A4 (fr) * 2017-11-08 2021-12-01 Advaxis, Inc. Peptides hétéroclitiques immunogènes issus de protéines associées au cancer et procédés d'utilisation de ces peptides
WO2019197567A2 (fr) 2018-04-11 2019-10-17 Enterome S.A. Peptides antigéniques pour la prévention et le traitement du cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ263050A (en) * 1993-03-05 1997-11-24 Cytel Corp Compositions of immunogenic peptides with hla-a2.1 binding motifs
AU2658897A (en) * 1996-03-21 1997-10-10 Epimmune, Inc. Hla-a2.1 binding peptides and their uses
WO1998004284A1 (fr) * 1996-07-25 1998-02-05 The Johns Hopkins University Nouveaux genes de l'herpesvirus associe a la maladie de kaposi
US5783567A (en) * 1997-01-22 1998-07-21 Pangaea Pharmaceuticals, Inc. Microparticles for delivery of nucleic acid

Also Published As

Publication number Publication date
CN1452634A (zh) 2003-10-29
EP1263775A1 (fr) 2002-12-11
WO2001062776A1 (fr) 2001-08-30
JP2003524016A (ja) 2003-08-12
MXPA02008219A (es) 2005-06-30
EP1263775A4 (fr) 2004-10-06
BR0017136A (pt) 2003-02-25
AU2000232427A1 (en) 2001-09-03

Similar Documents

Publication Publication Date Title
US7252829B1 (en) HLA binding peptides and their uses
EP1917970B1 (fr) Peptides se fixant au Hla et leurs utilisations
AU725550B2 (en) HLA binding peptides and their uses
CA2248667C (fr) Peptides de fixation de hla-a2.1 et leurs utilisations
EP1911461A2 (fr) Peptides de liaisons HLA de classe I et II et leurs utilisations
CA2400215A1 (fr) Peptides de liaison hla et utilisations de ces derniers
JP2010090167A (ja) Ｈｌａ結合ペプチドおよびそれらの用途
US20020177694A1 (en) Hla binding peptides and their uses
CA2420225A1 (fr) Peptides de fixation de hla-a2.1 et leurs utilisations
EP1320377B1 (fr) Peptides de liaison aux hla et leurs utilisations
CA2421448A1 (fr) Peptides de fixation de hla et leurs utilisations
EP1767542B1 (fr) Peptides de fixation de HLA-A2.1 et leurs utilisation
KR20030036139A (ko) Ｈｌａ 결합 펩티드 및 이의 용도
JP2010001303A (ja) Ｈｌａ結合ペプチド及びその使用

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20130802